Oncology & Cancer

Blincyto approval expanded for specific leukemia

(HealthDay)—The U.S. Food and Drug Administration says it has expanded approval for Blincyto (blinatumomab) to include adults and children with B-cell precursor acute lymphoblastic leukemia who are in remission but who ...

Oncology & Cancer

The calling card of aggressive thyroid cancer

A new discovery from University of Alberta scientists represents an important milestone in the fight against thyroid cancer. In a study published in EBioMedicine and recently presented at the American Thyroid Association ...

page 3 from 11